Market Cap | 658.97M | P/E | - | EPS this Y | 6.50% | Ern Qtrly Grth | - |
Income | -234.63M | Forward P/E | -1.93 | EPS next Y | -5.70% | 50D Avg Chg | -15.00% |
Sales | 130k | PEG | 0.35 | EPS past 5Y | - | 200D Avg Chg | -19.00% |
Dividend | N/A | Price/Book | 0.84 | EPS next 5Y | -7.90% | 52W High Chg | -70.00% |
Recommedations | 2.20 | Quick Ratio | 15.82 | Shares Outstanding | 254.94M | 52W Low Chg | 49.00% |
Insider Own | 15.54% | ROA | -18.18% | Shares Float | 127.35M | Beta | -0.56 |
Inst Own | 72.59% | ROE | -31.53% | Shares Shorted/Prior | 18.23M/10.38M | Price | 2.64 |
Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 1,102,580 | Target Price | 6.33 |
Oper. Margin | -454,392.33% | Earnings Date | - | Volume | 815,610 | Change | -5.38% |
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
HC Wainwright & Co. | Buy | Feb 29, 24 |
HC Wainwright & Co. | Buy | Nov 9, 23 |
JP Morgan | Neutral | Aug 28, 23 |
HC Wainwright & Co. | Buy | May 5, 23 |
HC Wainwright & Co. | Buy | Mar 2, 23 |
Morgan Stanley | Equal-Weight | Jan 24, 23 |
Morgan Stanley | Equal-Weight | Nov 14, 22 |
Goldman Sachs | Neutral | Nov 11, 22 |
HC Wainwright & Co. | Buy | Oct 17, 22 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Bishop Hans Edgar | Director Director | Sep 08 | Option | 0.10 | 145,380 | 14,538 | 4,685,614 | 09/09/22 |